Marumo Satoshi, Shirata Masahiro, Sakuramoto Minoru, Fukui Motonari
Respiratory Disease Center, Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan.
BMJ Case Rep. 2014 Dec 17;2014:bcr2014207996. doi: 10.1136/bcr-2014-207996.
There is no established therapeutic option for corticosteroid (CS) refractory drug-induced interstitial lung disease (DILD). We report a case of CS refractory severe DILD successfully treated with recombinant human soluble thrombomodulin (rhTM). A 64-year-old Japanese man was admitted with symptoms of fever, dry cough and dyspnoea. A chest radiograph showed bilateral infiltrations. DILD from Nijutsutou, a Chinese medicine, was suspected based on a history of similar interstitial lung disease after its administration 4 years prior and a positive drug-induced lymphocyte stimulation test. Nijutsutou was promptly discontinued and high doses of CS administered, but the patient's bilateral infiltrations remained unimproved. Since coagulation tests also indicated a rapid aggravation of coagulopathy, rhTM was added to the CS therapy. The patient's lung infiltration ameliorated and plasma levels of D-dimer and high morbidity group box 1 (HMGB1) decreased. rhTM may be an alternative agent for CS refractory DILD. Further study is necessary to confirm this.
对于皮质类固醇(CS)难治性药物性间质性肺病(DILD),目前尚无既定的治疗方案。我们报告了一例CS难治性重度DILD患者,经重组人可溶性血栓调节蛋白(rhTM)成功治疗。一名64岁的日本男性因发热、干咳和呼吸困难症状入院。胸部X线片显示双侧浸润。根据4年前服用中药二陈汤后出现类似间质性肺病的病史以及药物诱导淋巴细胞刺激试验阳性,怀疑为二陈汤所致的DILD。立即停用二陈汤并给予高剂量CS,但患者的双侧浸润未见改善。由于凝血检查也显示凝血功能迅速恶化,因此在CS治疗中加用了rhTM。患者的肺部浸润改善,D-二聚体和高迁移率族蛋白B1(HMGB1)的血浆水平降低。rhTM可能是CS难治性DILD的替代药物。需要进一步研究来证实这一点。